Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 73–96 of 297
Acceleration of Lactate Uptake and Utilization Contributes to Neuroprotective Action of FGF21 Involved in Naturally Aging Mice
FGF21 enhances lactate uptake and utilization in the aging brain, protecting against neuroinflammation-driven cognitive decline. This mechanism reveals how metabolic efficiency at the cellular level directly influences neuronal resilience during aging.
Telomerase Knockout in Myeloid Cells Predisposes Mice to Foam Cell Formation, Dyslipidemia, Lung Fibrosis, and Cardiac Dysfunction
Telomerase (TERT) in myeloid cells prevents senescence and pro-inflammatory polarization through mechanisms independent of telomere length. Loss of myeloid TERT drives foam cell formation, dyslipidemia, pulmonary fibrosis, and cardiac dysfunction—establishing TERT as essential for preventing aging-associated multi-organ pathology.
Featured Cover
Plasma proteomic analysis of Swiss centenarians identifies a distinct protein signature associated with preserved youthfulness and longevity. This proteomic fingerprint offers a measurable biomarker set for aging trajectories and potential intervention targets.
Rubedo reports early clinical signal for senotherapeutic drug
Phase 1 data for RLS-1496, a GPX4 modulator, demonstrate safety and dose-dependent target engagement alongside reductions in senescence markers and clinical improvement in inflammatory skin conditions. The drug operates through a dual mechanism: clearing senescent cells via ferroptosis while restoring redox balance in stressed neighboring cells, representing a shift toward cellular recalibration rather than indiscriminate senescent cell clearance.
FGF21‐Mediated Upregulation of SIRT1 Delays Intervertebral Disc Degeneration by Promoting PINK1/Parkin Dependent Mitophagy Through Deacetylation of FOXO3
FGF21 activates a cellular repair pathway in spinal disc cells by upregulating SIRT1, which deacetylates FOXO3 and triggers mitochondrial autophagy, thereby suppressing cell senescence and slowing intervertebral disc degeneration. This identifies a targetable molecular axis with direct relevance to preventing age-related spinal structural decline and associated disability.
Rejuvenation Roundup February 2026
A February 2026 research roundup covering advances in cellular reprogramming, senolytic effectiveness, immune cell restoration, and cognitive interventions demonstrates multiple convergent pathways for addressing age-related decline. The collective findings suggest that aging is modifiable across multiple biological domains, with implications for clinical translation in vision, neurological, and metabolic disease.
MicroRNA profiles in plasma-derived extracellular vesicles across the human lifespan
Plasma extracellular vesicles carrying microRNAs show age-specific expression patterns that correlate with biological aging across the human lifespan. These circulating biomarkers may serve as measurable indicators of systemic aging processes and inform stratification of longevity risk.
Cellbricks Therapeutics secures €10 million to advance tissue implants
Cellbricks Therapeutics secured €10 million to advance biofabricated tissue implants toward clinical use, focusing initially on adipose tissue for soft tissue defects and wound healing. The funding supports preclinical validation and manufacturing scale-up for vascularized tissue alternatives to synthetic reconstructive implants.
Garm adds Klotho to cell and gene therapy platform in Roatan
Garm LLC expanded its non-permanent plasmid gene therapy platform to include Klotho alongside existing follistatin and VEGF therapies, targeting mitochondrial function, inflammation reduction, oxidative stress management, and metabolic aging. The platform operates in Roatan, Honduras, positioning itself as a personalized longevity intervention without permanent genetic modification.
Cells that heal? New Parkinson’s trial sparks hope
A Phase II clinical trial of XS411, a stem cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease, has advanced based on encouraging Phase I results showing improved motor function and no adverse events. The approach represents a shift from symptomatic management toward cellular repair, potentially restoring function rather than merely masking decline.
Peptide Evidence Gap Closes With Transparent AI Reviews
Evipedia, the Forever Healthy Foundation's evidence platform, has launched a dedicated peptides section covering 24 compounds with structured, transparently auditable reviews using an AI-assisted framework. This addresses a critical gap in longevity medicine where peptide interventions have outpaced robust human evidence, creating a need for systematic assessment to distinguish hypothesis from clinical meaningfulness.
AGGF1 and SESN2 preserve endothelial function in aging
AGGF1, a protein that declines with age and hypertension, preserves blood vessel function by regulating SESN2 expression and reducing oxidative stress. This pathway offers a mechanistic target for intervening in age-related blood pressure elevation before it becomes established disease.
First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences has received FDA clearance to begin the first human trial of cellular reprogramming, testing ER-100 against age-related vision diseases. This represents the first clinical translation of partial reprogramming technology, moving a three-decade research program from laboratory validation into human application.
Dopaminergic Cell Therapy Targets Neurodegeneration in Parkinson's
Aspen Neuroscience's sasineprocel, an autologous cell therapy derived from a patient's own skin cells and differentiated into dopaminergic neurons, has received FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease based on Phase 1/2a data showing early clinical activity and favorable safety. This designation accelerates regulatory pathway and marks a shift toward personalized cellular replacement strategies rather than pharmacological symptom management.
In Vitro Modeling of Age‐Associated Lipid Mediator's Impact on Vascular Biology Following Platelet Concentrate Transfusion
Lipid mediators in platelet transfusions—particularly lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate—decline with donor age and correlate with adverse transfusion reactions through altered platelet and endothelial cell activation. This finding suggests that donor age-related changes in lipid signaling directly influence transfusion safety and vascular biology.
Senescent fibroblast subtypes drive pulmonary fibrosis progression
Senescent fibroblasts—cells that have stopped dividing but remain metabolically active—exhibit distinct subpopulations with different DNA damage responses, a finding that clarifies how these cells contribute to idiopathic pulmonary fibrosis. This heterogeneity explains why standard anti-senescence approaches may fail in IPF and points toward subtype-specific interventions to halt progressive lung scarring.
Diosgenin Restores Muscle Stem Cell Function in Aging
Diosgenin, a plant-derived compound, activates SIRT1/PGC-1α signaling to restore satellite cell function and muscle mass in aged mice, demonstrating a mechanistic pathway relevant to age-related sarcopenia. The compound increased grip strength, exercise endurance, and muscle fiber size while upregulating myogenic markers and growth factors essential for muscle regeneration.
Progerin Blocks Its Own Clearance—Selinexor Restores the Pathway
Progerin, the mutant protein driving Hutchinson-Gilford progeria syndrome, blocks autophagy at its final stages—preventing lysosomes from clearing the toxic protein itself. Selinexor restores this clearance mechanism by reactivating the autophagy-lysosome pathway, offering a therapeutic target for this severe premature aging condition.
Donor bone marrow banking restores immune cell production
Ossium Health has developed the first bank of organ donor-derived bone marrow and achieved neutrophil engraftment in all 28 patients treated to date, demonstrating a viable approach to stem cell therapy for hematologic and musculoskeletal conditions. The company's inclusion on Forbes' Next Billion-Dollar Startups list reflects growing investor confidence in cellular regeneration therapies.
Biotech lands $45m to drug the undruggable
Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.
Longeveron publishes stem cell therapy frailty trial results
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
Senescent Microglia Mapping Reveals White Matter Targets
Senescent microglia accumulate in aged brain white matter and can be identified through spatial mapping techniques. Senotherapeutic interventions reduce this accumulation, suggesting a tractable target for preserving neurological function during aging.
Circulating levels of insulin-like growth factor binding protein 7 are associated with risks of chronic diseases and death
Circulating insulin-like growth factor binding protein 7 (IGFBP7) independently predicts risk of chronic disease and mortality across multiple conditions, suggesting it functions as a systemic biomarker of aging and physiological decline. Measurement of IGFBP7 may offer clinicians a quantifiable indicator of disease susceptibility that extends beyond traditional risk factors.
AI-Designed Peptides Target Oral Delivery Breakthrough
LG AI Research and D&D Pharmatech are partnering to use artificial intelligence to design peptide therapeutics, compressing the molecular discovery timeline by generating novel candidates based on pattern recognition rather than manual search. This collaboration addresses both the design challenge and the delivery barrier that has limited peptide drug development, positioning AI as an active research participant rather than a background tool.